Autolus announces the pricing of its initial public offering

UCLB spinout, Autolus, announced today the pricing of its initial public offering in the United States of 8,823,530 American Depositary Shares (“ADSs”) representing 8,823,530 ordinary shares at an initial public offering price of $17.00 per ADS for total gross proceeds of approximately $150.0 million.

The clinical stage biopharmaceutical company was founded upon the work of Dr Martin Pule, a UCL academic, clinical haematologist and thought leader in T-cell engineering.

Read the full press release here